Ontology highlight
ABSTRACT: Background
Factor XI (FXI) is a promising target for novel anticoagulants because it shows a strong relation to thromboembolic diseases, while fulfilling a mostly supportive role in hemostasis. Anticoagulants targeting FXI could therefore reduce the risk for thrombosis, without increasing the chance of bleeding side effects.Objectives
To generate nanobodies that can interfere with FXIa mediated activation of factor IX (FIX).Methods
Nanobodies were selected for binding to the apple 3 domain of FXI and their effects on FXI and coagulation were measured in purified protein systems as well as in plasma-based coagulation assays. Additionally, the binding epitope of selected nanobodies was assessed by hydrogen-deuterium exchange mass spectrometry.Results
We have i
SUBMITTER: Bar Barroeta A
PROVIDER: S-EPMC9795894 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature